Hexa His tag peptide Cheson BD Bennett JM Kopecky KJ

[32] Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid Leukemia. J Clin Oncol 2003;21(24):4642–9.
[33] Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prog-nostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40(5):373–83. [34] Cella D. The functional assessment of Cancer therapy-Anemia (FACT-an) scale: Hexa His tag peptide new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997;34(3 Suppl 2):13–9.
[35] Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE. Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of Cancer therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002;24(6):547–61.
[36] Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85(5):365–76.
[38] Greenberg DB, Gray JL, Mannix CM, Eisenthal S, Carey M. Treatment-related fatigue and serum interleukin-1 levels in patients during external beam irradiation for pros-tate cancer. J Pain Symptom Manage 1993;8(4):196–200.
[40] Bower JE, Ganz PA, Aziz N, Fahey JL. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 2002;64(4):604–11. [41] Wratten C, Kilmurray J, Nash S, Seldon M, Hamilton CS, O'Brien PC, et al. Fatigue dur-ing breast radiotherapy and its relationship to biological factors. Int J Radiat Oncol Biol Phys 2004;59(1):160–7. [42] Rich T, Innominato PF, Boerner J, Mormont MC, Iacobelli S, Baron B, et al. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal can-cer. Clin Cancer Res 2005;11(5):1757–64.
[43] Wang XS, Shi Q, Williams LA, Mao L, Cleeland CS, Komaki RR, et al. Inflammatory cy-tokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav Immun 2010; 24(6):968–74.
[49] Black DS, Slavich GM. Mindfulness meditation and the immune system: a systematic review of randomized controlled trials. Ann N Y Acad Sci 2016;1373(1):13–24. [50] Creswell JD, Irwin MR, Burklund LJ, Lieberman MD, Arevalo JM, Ma J, et al. Mindfulness-based stress reduction training reduces loneliness and pro-inflammatory gene expression in older adults: a small randomized controlled trial. Brain Behav Immun 2012;26(7):1095–101. [51] Bower JE, Crosswell AD, Stanton AL, Crespi CM, Winston D, Arevalo J, et al. Mindful-ness meditation for younger breast cancer survivors: a randomized controlled trial. Cancer 2015;121(8):1231–40.
[56] Rao AV, Valk PJ, Metzeler KH, Acharya CR, Tuchman SA, Stevenson MM, et al. Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitiv-ity in patients with acute myeloid leukemia. J Clin Oncol 2009;27(33):5580–6. [57] Kopf M, Bachmann MF, Marsland BJ. Averting inflammation by targeting the cyto-kine environment. Nat Rev Drug Discov 2010;9(9):703–18. [58] Cella D, Lai JS, Chang CH, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 2002;94(2):528–38.
Contents lists available at ScienceDirect
The Breast
Original article
Agreement between digital breast tomosynthesis and pathologic tumour size for staging breast cancer, and comparison with standard mammography